DexCom, Inc.

Registration Deadline:

10/15/2024

Submit Your Information

A securities class action has been filed in the USDC — S.D.CA. against DexCom, Inc. (DXCM) (“DexCom” or the “Company”), on behalf of all persons or entities that purchased or otherwise acquired DexCom common stock between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”).

 

DexCom is an international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. DexCom’s G7 continuous glucose monitoring system, designed and distributed as an upgrade over the prior G6 model, was launched in early 2023.

 

The claim arises on July 25, 2024, Dexcom announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024.

 

The complaint alleges that the Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of DexCom’s salesforce; notably, that it was not truly equipped to execute on the Company’s perceived growth potential. Such statements absent these material facts caused Plaintiff and other shareholders to purchase DexCom’s securities at artificially inflated prices, thereby harming investors.

 

On this news, the price of DexCom’s common stock declined dramatically. From a closing market price of $107.85 per share on July 25, 2024, DexCom’s stock price fell to $64.00 per share on July 26, 2024, a decline of about 40.66% in the span of just a single day.

 

If you purchased DexCom common stock securities during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

 

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.